SYNTAX AT 4 YEARS. EACT 2011, LISBON
Last week, Dr Patrick Serruys was our spokesman at the European Association of Cardiothoracic Surgeons Annual Meeting in Lisbon. He was there to present the 4 years follow-up of the Syntax trial. The Syntax trial, which began enrollment in 2004, is a study of 1,800 patients with LMS and 3VD CAD randomised to CABG or PCI using the TAXUS stent. At the 1st year, PCI was inferior to CABG, driven mainly by the higher TLR rate in PCI. There was no difference in the hard endpoints of death/CVA/AMI. At 2 years the trend was basically the same with the curve diverging slightly. Last year ( 3 years ), the curve was still diverging but the CVA rates ( which was more in the CABG arm at year one ) had flattened out. Now at year 4, the CABG arm was clearly better as the end points of death ( CV and all cause mortality ) and AMIs were both higher in the PCI arms and the stroke rates were flat for the last 2 years.
SYNTAX 4-year cumulative results
Outcome | CABG surgery, n=819 (%) | PCI, n=879 (%) | p |
MACCE | 23.6 | 33.5 | <0.001 |
Death/stroke/MI | 14.6 | 18 | 0.07 |
All-cause mortality | 8.8 | 11.7 | 0.048 |
Cardiac death | 4.3 | 7.6 | 0.004 |
Stroke | 3.7 | 2.3 | 0.06 |
MI | 3.8 | 8.3 | <0.001 |
Repeat revascularization | 11.9 | 23 | <0.001 |
In the current scheme of things, this will be my strategy.
No comments:
Post a Comment